Novo Nordisk has announced a €432 million ($501 million) investment to expand its manufacturing facility in Athlone, Ireland, specifically targeting the production of its oral GLP-1 obesity medication, the Wegovy pill. This strategic move involves retrofitting a site acquired from Alkermes to create a “critical hub” for markets outside the U.S. The expansion aims to bo...
follow.it gives you an easy way to subscribe to THEORetically Speaking -'s news feed! Click on Follow below and we deliver the updates you want via email, phone or you can read them here on the website on your own news page.
You can also unsubscribe anytime painlessly. You can even combine feeds from THEORetically Speaking - with other site's feeds!
Title: HealthEconomics.com - RWE, HEOR, and Market Access Content for Industry Professionals